Andere Sprachen Aerovate Therapeutics, Inc.

Aktien

A3CTMQ

US0080641071

AVTE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
20.29 ^USD	-2.22%		-6.71%	-10.34%

12.04.	Aerovate Therapeutics Insider verkaufte Aktien im Wert von $334,478, laut einer aktuellen SEC Einreichung	MT
04.04.	Aerovate Therapeutics Insider verkaufte Aktien im Wert von $300.033, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aerovate Therapeutics : May 2024 Corporate Presentation	02.05.
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	12.04.
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	04.04.
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference	27.03.
Aerovate Therapeutics Q4 Loss Widens	25.03.
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	25.03.
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights	25.03.
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing	21.03.
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair	06.03.
Aerovate Therapeutics, Inc. Announces Board Changes	06.03.
Aerovate Therapeutics : March 2024 Corporate Presentation	01.03.
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing	08.12.
Aerovate Therapeutics : December 2023 Corporate Presentation	01.12.
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing	30.11.
Aerovate Therapeutics Completes Enrollment in Phase 2b Portion of Trial for Treatment of Pulmonary Arterial Hypertension	20.11.
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	20.11.
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	20.11.
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aerovate Therapeutics, Inc.

Aktien

A3CTMQ

US0080641071

AVTE

Andere Sprachen

Filter